InvestorNewsBreaks - HeartBeam Inc. (NASDAQ: BEAT) Submits FDA Application for 12-Lead ECG Synthesis Software

Stock Information for Heartbeam Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Heartbeam Inc.

HeartBeam Reports Fourth Quarter and Full Year 2024 Results
HeartBeam to Participate at Upcoming Conferences in Dana Point, California, March 16-21, 2025
HeartBeam to Host Fourth Quarter Full Year 2024 Results Conference Call on Thursday, March 13, 2025 at 4:30 p.m. Eastern Time
HeartBeam Announces Exercise and Closing of Underwriter's Over-Allotment Option for Public Offering of Common Stock
HeartBeam Announces Pricing of $10.0 Million Underwritten Public Offering of Common Stock
HeartBeam Achieves Major Milestone with FDA Submission for its Groundbreaking 12-Lead ECG Synthesis Software
HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference
HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.